$44.88
0.18[0.40%]
At close: Apr 26
$44.88
0[0.00%]
After Hours: 7:58PM EDT
Bristol-Myers Squibb
(NYSE:BMY)Latest News for Bristol-Myers Squibb Stock (NYSE:BMY)
Bristol-Myers Squibb Stock (NYSE: BMY)
Categories: All
Friday, April 26, 2024
- BMO Capital Maintains Market Perform on Bristol-Myers Squibb, Lowers Price Target to $48Benzinga Newsdesk - 1 day ago
- Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst InsightsBenzinga Insights - 1 day ago
- Barclays Maintains Equal-Weight on Bristol-Myers Squibb, Lowers Price Target to $43Benzinga Newsdesk - 2 days ago
- Bristol Myers Says EMA's CHMP Recommended Approval Of Opdivo Combination With Cisplatin, Gemcitabine For First-line Treatment Of Adult Patients With Unresectable Or Metastatic Urothelial CarcinomaBenzinga Newsdesk - 2 days ago
- Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 PointsAvi Kapoor - 2 days ago
Thursday, April 25, 2024
- Bristol-Myers Q1 Loss Narrower Than Expected, Sales BeatZacks - 2 days ago
- Crude Oil Moves Higher; Bristol Myers Squibb Shares Fall After Q1 ResultsAvi Kapoor - 2 days ago
- Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionAvi Kapoor - 2 days ago
- Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion AcquisitionsVandana Singh - 2 days ago
- Bristol-Myers Squibb shares are trading lower following Q1 earnings.Benzinga Newsdesk - 3 days ago
- Bristol Myers Squibb Revises 2024 Adjusted EPS Guidance From $7.10-$7.40 To $0.40-$0.70 Versus Consensus Of $0.66, Reflecting The Impact Of Recent TransactionsBenzinga Newsdesk - 3 days ago
- Bristol Myers Squibb Says It Is Executing Strategic Productivity Initiative To Deliver ~$1.5B In Cost Savings, The Majority Of Which Will Be Reinvested To Fund Innovation And Drive GrowthBenzinga Newsdesk - 3 days ago
- Bristol-Myers Squibb Q1 2024 Adj EPS $(4.40) Beats $(4.44) Estimate, Sales $11.865B Beat $11.458B EstimateBenzinga Newsdesk - 3 days ago
- US Stocks Brace For Negative Start Amid Tech Earnings Disappointments, Caution Ahead Of Data: 'Worst Of This Two-Week Decline Is Behind Us,' Says AnalystShanthi Rexaline - 3 days ago
Wednesday, April 24, 2024
Tuesday, April 23, 2024
Sunday, April 21, 2024
Friday, April 19, 2024
Thursday, April 18, 2024
Monday, April 15, 2024
Friday, April 12, 2024
Thursday, April 11, 2024
Wednesday, April 10, 2024
Tuesday, April 09, 2024
Monday, April 08, 2024
- Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain MutationVandana Singh - Apr 8, 2024, 2:00PM
- Bristol Myers Squibb Announces KRAZATI In Combination With Cetuximab Demonstrates Clinically Meaningful Activity As A Targeted Treatment Option For Patients With Previously Treated KRAS G12C-Mutated Locally Advanced Or Metastatic Colorectal CancerBenzinga Newsdesk - Apr 8, 2024, 11:31AM
- Bristol Myers' $14B Bet On Schizophrenia - Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other AntipsychoticsVandana Singh - Apr 8, 2024, 10:31AM
- Reported Saturday, Bristol Myers Squibb Presented New Interim Long-Term Efficacy Data From The EMERGENT-4 Trial Evaluating Karxt In Schizophrenia At The 2024 Annual Congress Of The SIRSBenzinga Newsdesk - Apr 8, 2024, 3:11AM
Friday, April 05, 2024
- FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary CancerVandana Singh - Apr 5, 2024, 1:37PM
- At An Estimated Median Duration Of Follow-Up Of 15.9 Months At The Primary PFS Analysis, Abecma More Than Tripled The Primary Endpoint Of PFS Compared With Standard RegimensBenzinga Newsdesk - Apr 5, 2024, 9:09AM
- U.S. FDA Approves Bristol Myers Squibb And 2seventy bio's Abecma For Triple-Class Exposed Relapsed Or Refractory Multiple Myeloma After Two Prior Lines Of Therapy; Abecma Tripled Progression-Free Survival Compared To Standard Regimens In The Phase 3 KarMMa-3 trial, With A 51% Reduction In Risk Of Disease Progression Or Death And A Well-Established Safety ProfileBenzinga Newsdesk - Apr 5, 2024, 9:07AM
Thursday, April 04, 2024
Wednesday, April 03, 2024
- Standard BioTools Announces Multi-Year Strategic Engagement With Bristol Myers Squibb For Use Of The SomaScan Platform For Translational Medicine Research Through 2026Benzinga Newsdesk - Apr 3, 2024, 4:02PM
- Reported Earlier, European Commission Expands Approval Of Bristol Myers Squibb's Reblozyl® To Include First-Line Treatment Of Transfusion-Dependent Anemia In Adults With Lower-Risk Myelodysplastic SyndromesBenzinga Newsdesk - Apr 3, 2024, 2:31AM
Monday, April 01, 2024
Thursday, March 28, 2024
- Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint Of Progression-Free Survival For Patients With Pretreated KRASG12C-Mutated Locally Advanced Or Metastatic Non-Small Cell Lung CancerBenzinga Newsdesk - Mar 28, 2024, 4:12PM
- Bristol Myers Squibb Provides Update On First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia For Crohn's Disease; Study Did Not Meet Its Primary Endpoint Of Clinical Remission At Week 12Benzinga Newsdesk - Mar 28, 2024, 4:02PM
- 10 Health Care Stocks With Whale Alerts In Today's SessionBenzinga Insights - Mar 28, 2024, 1:35PM
Wednesday, March 27, 2024
Tuesday, March 26, 2024
Thursday, March 21, 2024
Wednesday, March 20, 2024
- Bristol Myers Squibb's Abecma CAR T Cell Therapy Approved In European Union In Earlier Lines For Triple-Class Exposed Relapsed And Refractory Multiple MyelomaBenzinga Newsdesk - Mar 20, 2024, 4:46PM
- GenScript Losses Shrink On Strong Growth For Cancer Cell TherapyThe Bamboo Works - Mar 20, 2024, 11:30AM
- Bristol Myers Squibb's Phase 3 Checkmate-9DW Trial Of Opdivo (Nivolumab) Plus Yervoy (Ipilimumab) As First-line Treatment For Advanced Hepatocellular Carcinoma Met Its Primary Endpoint Of Improved Overall Survival Compared To Sorafenib Or LenvatinibBenzinga Newsdesk - Mar 20, 2024, 7:01AM